article thumbnail

Positron Corporation Joins Cardiac PET Industry Coalition (CPIC)

DAIC

Positron joins forces with the coalitions founding members, Bracco Diagnostics , CDL Nuclear Technologies and Siemens Healthcare who have come together to promote federal policies that advance health outcomes for patients with cardiovascular disease and improve the availability of cardiac PET diagnostics throughout the United States.

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS previously published a New Technology APC (Ambulatory Payment Classifications) code that covers the CardiAMP Cell Therapy investigational study procedure, including the BioCardia investigational products utilized to perform the study procedure, allowing the study centers to be reimbursed for the study procedure and products.

CMS 111
article thumbnail

Atria’s Independent Cardiology Play 

CardiacWire

The shift towards corporate and hospital-owned cardiology groups stems from a long list of factors like falling reimbursements, rising costs, and partners who want an exit. The Takeaway Whether or not Atria will succeed depends on outcomes for both physicians and patients.

article thumbnail

First-of-its-kind ACC Registry Tracks Cardiac Procedures Performed in Ambulatory Surgical Settings

DAIC

Recent shifts in third-party payer reimbursement, led by the Centers for Medicare and Medicaid , have resulted in continued trends of minimally invasive cardiac procedures on stable patients increasingly being performed outside of a hospital setting.

article thumbnail

HRS 2024: Innovation Meets Reality

DAIC

Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. The expo floor was a veritable candy store for the scientifically minded electrophysiologist, with displays of wares that promised to improve the clinician’s outcomes.

article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

Despite improvements with current medications and devices, heart failure remains at epidemic proportions and we now have an exciting opportunity for a therapy to improve important, objective outcomes, such as mortality and hospital re-admissions rates. “We The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

article thumbnail

Revolution Vibe CT System Now Available from GE Healthcare

DAIC

vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible. This innovative technology maximizes operational efficiency, enhances staff expertise, and delivers better patient outcomes, making it a wise long-term investment.